Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note published on Thursday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

FULC has been the subject of a number of other research reports. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $10.00 to $2.00 in a report on Thursday, September 12th. Royal Bank of Canada lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $15.00 to $4.00 in a report on Thursday, September 12th. Leerink Partners restated a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Finally, Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Stock Performance

FULC stock opened at $3.01 on Thursday. The company has a 50 day moving average price of $3.75 and a two-hundred day moving average price of $6.47. The stock has a market capitalization of $162.36 million, a P/E ratio of -9.71 and a beta of 2.24. Fulcrum Therapeutics has a one year low of $2.87 and a one year high of $13.70.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. National Bank of Canada FI raised its stake in shares of Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares in the last quarter. Walleye Capital LLC purchased a new position in Fulcrum Therapeutics in the third quarter valued at about $59,000. Intech Investment Management LLC acquired a new position in shares of Fulcrum Therapeutics during the third quarter worth about $62,000. Finally, Profund Advisors LLC purchased a new stake in shares of Fulcrum Therapeutics in the second quarter worth about $68,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.